Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
260.00    0.00 (0.00%)
Bid:
252.00
Ask:
257.00
Spread: 5.00 (1.984%)
Market Cap: £232.84m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

Trading Statement

18 May 2017 07:00

RNS Number : 4771F
Wilmington PLC
18 May 2017
 

18 May 2017

 

Wilmington plc

Q3 Trading Update

 

Wilmington plc ("Wilmington" or "the business") the provider of information, education and networking services in Risk & Compliance, Professional, and Healthcare knowledge areas is today providing a trading update for the nine-month period to 31 March 2017.

 

Trading Update

Group revenue was up 13% (up 8% in constant currency) during the nine months ended 31 March 2017. Overall, revenue is in line with expectations, with good organic growth coming from our core growth areas of Risk & Compliance and the Healthcare businesses. Revenue growth was further supported by good contributions from the acquisitions made over the last two years and from the beneficial impact of currency translation. Offsetting this growth was, as previously reported, declines in some areas of the Professional division and the legacy charities and data suppression businesses.

During the nine-month period, Wilmington continued to see growth in reported operating profits, although this profit growth has been partially offset as reported in the interim results by continued investment across the business particularly in the US and in the compliance training areas where we see significant scope for stronger growth in the medium term.

 

Operational Review

Risk & Compliance 

Risk & Compliance again delivered strong revenue growth up 11% driven mainly by compliance training. In support of this growth and as reported in the interim results, we have continued to invest in new products, in the new North American operation and in additional support staff to expand our infrastructure and drive ICA membership. We have also been successful recently in winning two large international training programs which will benefit the business over the summer and we have brought in additional resources accordingly. This additional resource has further impacted margins in the short term but is expected to benefit contribution in 2017/18. Further investment continues to be made in our new North American compliance training business and in Compliance Week to expand its geographical reach in terms of events and information coverage.

Professional

Revenue was up 5% benefitting from favourable currency translation and the strong maiden performance from SWAT as well as our other accountancy training operations. However, the division continues to see the impact of the challenging conditions within the legal market as well as the impact of the weaker start to the financial year for AMT albeit we have recently regained stability in the Asia Pacific market.

The process for the planned disposal of Ark is underway and negotiations continue with potential buyers. Whilst Project Sixth Gear will provide benefits to the whole group, much of the work is centred around integrating the training businesses making up the bulk of the Professional division. This initiative is progressing well and we are attracting high calibre applicants for the divisional head role.

Healthcare 

Revenue was up 23% driven by organic growth across the board from our healthcare businesses and acquisitions made over the last two years. This was partially offset by continued declines in our legacy non-healthcare data suppression and charities businesses which make up around 20% of the division. HSJ, acquired on 31 January 2017 has also performed well and the HSJ team has been transferred to our Underwood Street premises. Integration is progressing on plan and is expected to be largely completed by the end of our 2016/17 financial year.

Cash Flow

Net debt as at 31 March 2017 was £51.4m (2016: £34.5m). This reflects strong cash generation and includes £20.3m paid in cash for two acquisitions made during the period. The Group has an overall borrowing facility of £85m which was extended from £65m in January 2017.

Adjusted measures

Effective from 30 June 2017 Wilmington will include share based payments costs within its definition of adjusted results. Share based payment costs amounted to £0.6m in 2015/16 and are not expected to be materially different during 2016/17.

Outlook

Wilmington continues to see the trends of tighter regulatory control and more complex legislation being implemented in most of our key markets, which in turn is driving demand for many of our products and services. We have and will continue to invest in our Compliance business to provide the infrastructure and support for anticipated future growth.

Despite the continued investment in infrastructure, the financial performance is in line with the Board's expectations and Wilmington is on track to deliver against expectations for the full year.

The information communicated in this announcement is inside information for the purposes of Article 7 of Market Abuse Regulation No. 596/2014

 

-End-

 

For further information, please contact:

Wilmington plc

Pedro Ros, Chief Executive Officer

Tony Foye, Chief Financial Officer

 

FTI Consulting

Charles Palmer / Emma Appleton / Adam Davidson

 

020 7422 6800

 

 

 

020 3727 1000

Notes to Editors

 

Wilmington plc is the recognised knowledge leader and partner of choice for information, education and networking in Risk & Compliance, Professional and Healthcare areas. Capitalised at approximately £210 million, Wilmington floated on the London Stock Exchange in 1995.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBVNRBWAVAAR
Date   Source Headline
1st Dec 20149:07 amRNSVoting Rights Announcement
20th Nov 20143:47 pmRNSShareholding Announcement
13th Nov 20143:40 pmRNSHolding(s) in Company
6th Nov 20145:11 pmRNSAGM Results 2014
6th Nov 20147:00 amRNSInterim Management Statement
3rd Nov 20141:39 pmRNSVoting Rights
27th Oct 201411:33 amRNSCorrection: Share Awards
20th Oct 20146:17 pmRNSCorrection: Share Awards
20th Oct 20145:10 pmRNSDirector/PDMR Shareholding
20th Oct 20145:09 pmRNSShare Awards
17th Oct 20143:54 pmRNSHolding(s) in Company
10th Oct 20144:16 pmRNSHolding(s) in Company
1st Oct 20141:46 pmRNSTotal Voting Rights
23rd Sep 201412:15 pmRNSShare Awards
18th Sep 20147:00 amRNSFinal Results
1st Sep 20145:16 pmRNSVoting Rights Announcement
1st Aug 20147:00 amRNSVoting Rights and Capital
14th Jul 20142:58 pmRNSHolding(s) in Company
14th Jul 20142:55 pmRNSHolding(s) in Company
1st Jul 201411:32 amRNSVoting Rights and Capital
23rd Jun 20149:00 amRNSNotice of Results
19th Jun 201411:05 amRNSHolding(s) in Company
12th Jun 20147:00 amRNSCEO Appointment
5th Jun 20145:26 pmRNSHolding(s) in Company
2nd Jun 201412:44 pmRNSTotal Voting Rights
2nd Jun 20149:00 amRNSHolding(s) in Company
22nd May 20142:22 pmRNSHolding(s) in Company
13th May 20147:00 amRNSInterim Management Statement
2nd May 20142:04 pmRNSVoting Rights & Capital
9th Apr 201412:36 pmRNSHolding(s) in Company
2nd Apr 201410:55 amRNSTotal Voting Rights
31st Mar 20144:30 pmRNSHolding(s) in Company
3rd Mar 20149:40 amRNSVoting Rights and Capital
25th Feb 20147:01 amRNSRetirement of Chief Executive
25th Feb 20147:00 amRNSInterim Results
17th Feb 20142:58 pmRNSHolding(s) in Company
4th Feb 20141:50 pmRNSVoting Rights and Capital
2nd Jan 20142:12 pmRNSVoting Rights and Capital
20th Dec 201311:32 amRNSNotice of Results
2nd Dec 20135:57 pmRNSTotal Voting Rights
19th Nov 20137:00 amRNSHolding(s) in Company
11th Nov 20134:48 pmRNSHolding(s) in Company
5th Nov 20133:39 pmRNSResult of AGM
5th Nov 20137:00 amRNSInterim Management Statement
4th Nov 201312:23 pmRNSTotal Voting Rights
24th Oct 201311:52 amRNSShare Awards
4th Oct 201311:42 amRNSHolding(s) in Company
2nd Oct 20134:31 pmRNSDirector/PDMR Shareholding
1st Oct 20134:51 pmRNSHolding(s) in Company
1st Oct 201311:33 amRNSVoting Rights and Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.